In fact, pembrolizumab, an antibody inhibitor of programmed cell death 1 (PD-1) receptor on T cells, which initially was approved to treat advanced melanoma, received additional approval for MMR-deficient solid cancers, representing the first time the FDA approved a cancer drug based on tumor genetics rather than tumor site [70,71]. Here, MRC1 is linked to neoplasm.